Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IARS siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of isoleucyl-tRNA synthetase (IARS), also known as IARS1. IARS is an enzyme primarily responsible for ligating isoleucine to its cognate tRNA, but it has also been implicated in non-canonical inflammatory signaling pathways. In the context of dermatological research, particularly psoriasis, IARS siRNA has been shown to inhibit the Jak2/STAT3/CXCL16 signaling pathway in human epidermal keratinocytes. By reducing IARS protein levels, the siRNA suppresses the production of pro-inflammatory cytokines and chemokines, including IL-6, IL-1β, CCL5, and CXCL16, thereby ameliorating psoriasis-like skin lesions in experimental models. This approach represents a potential therapeutic strategy for inflammatory skin diseases by modulating the aminoacyl-tRNA synthetase-mediated inflammatory axis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IARS siRNA.